https://pubmed.ncbi.nlm.nih.gov/38115203
Niraparib maintenance therapy in ovarian cancer patients in Japan is associated with increased creatinine levels, but the changes are reversible.
https://pubmed.ncbi.nlm.nih.gov/38115202
The study found that using a fluid warmer on cold-stored platelets can significantly reduce their ability to aggregate when triggered by ADP, with no significant effect on aggregation triggered by AA or collagen.
https://pubmed.ncbi.nlm.nih.gov/38115200
The working alliance between staff and patients with Schizophrenia Spectrum Disorder living in Residential Facilities is positively correlated, and is associated with factors such as patient education, employment status, lifetime hospitalization, psychopathology severity, and psychosocial functioning, as well as staff members’ age.
https://pubmed.ncbi.nlm.nih.gov/38115199
The ฮฑ-TOST procedure, a finite sample correction of the conservative TOST procedure, guarantees the test size of ฮฑ and is uniformly more powerful in average (bio)equivalence testing, as demonstrated in a case study on econazole nitrate deposition in porcine skin.
https://pubmed.ncbi.nlm.nih.gov/38115198
Synthesizing unsymmetrical squaraine dyes with different anchoring groups, this study found that the carboxylic acid anchoring group in SD3 dye resulted in a more efficient dye-sensitized solar cell (7.20%) compared to pyridyl anchoring groups in SD1 and SD2 dyes (2.34% and 0.84%, respectively), attributed to dye loading on TiO2’s acidic sites and aggregated structures.
https://pubmed.ncbi.nlm.nih.gov/38115197
This study found that achieving a balanced ratio of hydrophilic and hydrophobic components, around 10-15 wt% of each, in amphiphilic coatings results in superior fouling-release performance compared to traditional hydrophobic marine coatings.
https://pubmed.ncbi.nlm.nih.gov/38115196
The adhesion force of graphene in sphere-plane contacts changes with time and humidity according to a new model based on water contact angle theory and Bradley contact theory, which is consistent with experimental results.
https://pubmed.ncbi.nlm.nih.gov/38115195
This study developed a model to characterize the pharmacokinetics of subcutaneous nivolumab and predicted that a dose of 1200 mg SC every 4 weeks provides comparable exposures to approved and tested safe intravenous doses, informing the selection of this dose for phase III evaluation.